| Name | Magnolia Ridge |
|---|---|
| Location | 420 Dean Drive, Gardendale, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 148 |
| Occupancy Rate | 74.46% |
| Medicare ID (CCN) | 015133 |
| Legal Business Name | Sunbridge Gardendale Health Care Center, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1285684068 |
| Organization Name | SUNBRIDGE GARDENDALE HEALTH CARE CENTER, LLC |
| Doing Business As | MAGNOLIA RIDGE |
| Address | 420 Dean Dr, Gardendale, AL 35071 |
| Phone Number | 205-631-8709 |
News Archive
Although recent news coverage has linked long-distance air travel with the dangers of blood clots, few people have realized the increased risk for leg ulcers, as well.
Many clinicians believe that depression goes hand in hand with cognitive difficulties such as memory problems or difficulties concentrating and paying attention, but a recent review of nearly 20 years of literature conducted by researchers from UT Southwestern Medical Center has found that depression does not always lead to such impairments.
Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Although recent news coverage has linked long-distance air travel with the dangers of blood clots, few people have realized the increased risk for leg ulcers, as well.
Many clinicians believe that depression goes hand in hand with cognitive difficulties such as memory problems or difficulties concentrating and paying attention, but a recent review of nearly 20 years of literature conducted by researchers from UT Southwestern Medical Center has found that depression does not always lead to such impairments.
Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $9168 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 26.3 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.43 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 37.5 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.21 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.83 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.51 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.66 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.63 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.24 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.55 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 93.6 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.6 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 46.29 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.7 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.35 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 59.43 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 92.74 | 82.93 |
News Archive
Although recent news coverage has linked long-distance air travel with the dangers of blood clots, few people have realized the increased risk for leg ulcers, as well.
Many clinicians believe that depression goes hand in hand with cognitive difficulties such as memory problems or difficulties concentrating and paying attention, but a recent review of nearly 20 years of literature conducted by researchers from UT Southwestern Medical Center has found that depression does not always lead to such impairments.
Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.
ARIAD Pharmaceuticals, Inc. today announced that it is temporarily suspending the marketing and commercial distribution of Iclusig® (ponatinib), a treatment for patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), in the United States, while it continues to negotiate updates to the U.S. prescribing information for Iclusig and implementation of a risk mitigation strategy.
› Verified 5 days ago